Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant…

FDA picks a new strain for fall Covid vaccines. Here's what it means for your next shot.

The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most at-risk Americans this fall.

Moderna's New COVID Vaccine Takes Aim at Dangerous LP.8.1 Variant - FDA Review Begins

Moderna advances next-generation Spikevax formula designed for emerging variant LP.8.1. Learn about the new 2025-2026 COVID vaccine awaiting FDA review. Get Details